New findings published online in The FASEB Journal, may one day help clinicians predict the outcome of roux-en-Y gastric bypass surgerysurgery. In a study involving a small number of patients, researchers found that the serum stearic acid/palmitic acid (S/P) ratio was a reliable marker in predicting diabetes remission and assessing metabolic status. Ultimately, this study could help healthcare providers determine who might benefit the most from bariatric weight-loss surgery.
"Roux-en-Y gastric bypass surgery (RYGB), one of the most commonly used bariatric surgical procedures, showed the different efficacy in obese patients with diabetes," said Wei Jia, Ph.D., a researcher involved in the work and associate director of the Cancer Epidemiology Program at the University of Hawaii Cancer Center and also director of the Center for Translational Medicine at Shanghai Jiao Tong University Affiliated Sixth People's Hospital in Shanghai, China. "Our findings could help identify patients preoperatively who would respond most favorably to the surgery."
Jia and colleagues used two independent cohorts. The first was a longitudinal cohort of 38 obese patients with diabetes who achieved weight loss and diabetes remission after RYGB. About 32 percent of these patients showed recurrence of diabetes at the second year follow-up examination. Those patients who had higher levels of S/P before surgery had greater possibilities for diabetes remission after surgery. In the second cohort of 381 community-based human participants, overweight or obese patients with diabetes exhibited lower S/P than did body mass index-matched nondiabetic patients, which highlight the specific product-to-precursor ratios as novel markers in preoperative assessment of bariatric surgery. Adding the S/P ratio to the previously reported clinical panel of diabetes duration, HbA1c level, and fasting C-peptide level contributed a significant increase in the predictive potential.
"This is a very important new picture in the bariatric surgery field," said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. "Both the morbidity that necessitates the procedure and the procedure itself are steep challenges, and this study has the potential to greatly benefit patients going forward."
Submit to The FASEB Journal by visiting http://fasebj.msubmit.net, and receive monthly highlights by signing up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.
FASEB is composed of 30 societies with more than 125,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Linjing Zhao, Yan Ni, Haoyong Yu, Pin Zhang, Aihua Zhao, Yuqian Bao, Jiajian Liu, Tianlu Chen, Guoxiang Xie, Jun Panee, Wenlian Chen, Cynthia Rajani, Runmin Wei, Mingming Su, Weiping Jia, and Wei Jia. Serum stearic acid/palmitic acid ratio as a potential predictor of diabetes remission after Roux-en-Y gastric bypass in obesity. FASEB J. doi:10.1096/fj.201600927R ; http://www.fasebj.org/content/early/2016/12/22/fj.201600927R.abstract
Story Source: Materials provided by Scienmag